Antiangiogenic therapy enhances CAR-T cell efficacy in solid tumors: Insights from a hybrid multiscale model
Computer Methods and Programs in Biomedicine · 2026-08 · 283 · 109434
DOI: 10.1016/j.cmpb.2026.109434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computer Methods and Programs in Biomedicine, 2026-08. Verfasst von Sayyed Mohammad Ali Mortazavi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, Sharif University of Technology, Tehran, Iran. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 85 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES Despite the remarkable success of chimeric antigen receptor (CAR) T cells in hematological malignancies, their therapeutic efficacy in solid tumors is still limited, largely due to the insufficient infiltration of CAR-T cells and the immunosuppressive tumor microenvironment (TME). Recently, murine studies have shown that anti-angiogenic therapy can improve the efficacy of CAR-T cells. However, extensive research is required to unveil the underlying mechanism and develop effective therapeutic protocols. METHODS Here, we developed a hybrid discrete - continuous multi-scale computational model to study solid tumor growth, angiogenesis, and CAR-T cell infiltration. Our model considers the intravenous infusion of CAR-T cells, their extravasation through the endothelium, and their cytotoxic effect in the TME. Therefore, this model enables us to robustly investigate the impact of anti-angiogenic therapy on the efficacy of CAR-T cells. RESULTS Our findings showed that anti-angiogenic therapy enhances the delivery and efficacy of CAR-T cells in solid tumors. Subsequently, we evaluated different therapeutic regimens. The results revealed that although both adjuvant and neoadjuvant anti-angiogenic therapy can improve outcome, the neoadjuvant regimen yields higher survival rates. Moreover, our model suggested an optimal dosing schedule to maximize survival. CONCLUSIONS Our results provide profound insight into the therapeutic dynamics of combined anti-angiogenic and CAR-T cell therapy. Additionally, the model establishes a computational framework for selecting treatment regimens for clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mechanical Engineering, Sharif University of Technology, Tehran, Iran.
- Department of Mechanical Engineering, Sharif University of Technology, Tehran, Iran. Electronic address: firoozabadi@sharif.edu.
Zitieren
APA
Mortazavi, S. M. A., & Firoozabadi, B. (2026). Antiangiogenic therapy enhances CAR-T cell efficacy in solid tumors: Insights from a hybrid multiscale model. Computer Methods and Programs in Biomedicine, 283, 109434. https://doi.org/10.1016/j.cmpb.2026.109434
Vancouver
Mortazavi SMA, Firoozabadi B. Antiangiogenic therapy enhances CAR-T cell efficacy in solid tumors: Insights from a hybrid multiscale model. Computer Methods and Programs in Biomedicine. 2026;283:109434. doi:10.1016/j.cmpb.2026.109434
BibTeX
@article{Mortazavi2026,
author = {Mortazavi, Sayyed Mohammad Ali and Firoozabadi, Bahar},
title = {Antiangiogenic therapy enhances CAR-T cell efficacy in solid tumors: Insights from a hybrid multiscale model},
journal = {Computer Methods and Programs in Biomedicine},
year = {2026},
volume = {283},
pages = {109434},
doi = {10.1016/j.cmpb.2026.109434}
}
EUVIMED